Physician profile
Michaelle Benyehuda
NPI 1417581935
$793.03
in general payments reported to CMS, 2019-2025
12 companies · $34.34 in 2025
The $34.34 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $179 · 2023: $534 · 2024: $46.67 · 2025: $34.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $614.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $160.02 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $154.48 | 2022-2023 | Farxiga, Brilinta |
| Boston Scientific Corporation | $107.97 | 2022-2023 | Varithena Administration Pack, Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.65 | 2022-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $76.43 | 2022-2023 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $46.30 | 2023 | Inpefa |
| Janssen Pharmaceuticals, INC | $34.27 | 2023 | Xarelto |
| Angiodynamics, INC. | $31.72 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.06 | 2023-2025 | Lifevest |
| Abiomed | $26.16 | 2024 | Impella |
| Pfizer INC. | $24.44 | 2023 | |
| Biosense Webster, INC. | $19.53 | 2025 | Carto 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michaelle Benyehuda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.